Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 13;9(28):19508–19524. doi: 10.18632/oncotarget.24628

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2018 Hori et al.

This article is distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.

PMC Copyright notice

(A) Representative images of resected xenografts from each treatment group stained with four immunological markers. The expression levels of KLγ, Ki-67, TUNEL, and E-cadherin are noted. Expression levels of each marker in tumors of mice treated with KLγ siRNA compared to both the control group and the group of mice treated with negative control siRNA. The expression levels of KLγ and Ki-67 decreased in tumors of mice treated with KLγ siRNA. The expression levels of TUNEL and E-cadherin increased in tumors of mice treated with KLγ siRNA. (B) Treatment with KLγ siRNA suppressed the expression levels of KLγ mRNA in tumors of mice treated with KLγ siRNA, as measured by RT-PCR analysis. (C) Western blot analysis of protein extracted from resected xenografts in each treatment group. The expression levels of E-cadherin, N-cadherin, vimentin, phospho-AKT, phospho-ERK1/2, and actin (as a control) were noted. The expression level of E-cadherin was increased in tumors of mice treated with KLγ siRNA. The expression levels of N-cadherin and vimentin decreased in tumors of mice treated with KLγ siRNA.